| FDA Takes Prudent Tact In Response To Endo Compounding Lawsuit
FDA appears to be framing its policy on compounding of bulk substances by outsourcers differently to the courts than it is to Congress, one compounding attorney commented after reading the agency response to a lawsuit seeking to block FDA's interim policy on 503B compounding. However, multiple ...
|
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Friday, January 12, 2018
FDA Takes Prudent Tact In Response To Endo Compounding Lawsuit
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment